Biotech Analysts discuss the optimal treatment for oncogene driven solid tumors (relevant companies RVMD RLAY MRTX NUVL ORIC) on an Analyst/Industry conference call to be held on October 6 at 12 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVMD:
- JPMorgan biotech analysts hold an analyst/industry conference call
- Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
- Revolution Medicines participate in a conference call with JPMorgan
- Revolution Medicines price target raised to $47 from $37 at Stifel
- Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor